Insider Selling: Mesa Laboratories, Inc. (NASDAQ:MLAB) SVP Sells 472 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) SVP Brian David Archbold sold 472 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $97.12, for a total value of $45,840.64. Following the transaction, the senior vice president now owns 558 shares of the company's stock, valued at approximately $54,192.96. The trade was a 45.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mesa Laboratories Price Performance

NASDAQ MLAB traded up $1.97 on Wednesday, reaching $94.70. 164,868 shares of the stock traded hands, compared to its average volume of 53,589. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $155.12. The company has a market cap of $517.04 million, a price-to-earnings ratio of -255.83 and a beta of 0.88. The firm's fifty day simple moving average is $111.75 and its 200 day simple moving average is $125.47. The company has a quick ratio of 0.47, a current ratio of 0.63 and a debt-to-equity ratio of 0.48.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Friday, May 30th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend was Friday, May 30th. Mesa Laboratories's payout ratio is -172.97%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MLAB. Wells Fargo & Company reduced their price target on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research report on Friday, May 30th. Wall Street Zen lowered shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 30th.

Hedge Funds Weigh In On Mesa Laboratories

Several hedge funds have recently made changes to their positions in the business. State of Wyoming grew its position in Mesa Laboratories by 501.4% during the 1st quarter. State of Wyoming now owns 427 shares of the medical instruments supplier's stock worth $51,000 after purchasing an additional 356 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Mesa Laboratories in the 1st quarter valued at $67,000. Amundi boosted its stake in shares of Mesa Laboratories by 81.6% during the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock worth $91,000 after acquiring an additional 297 shares in the last quarter. Resona Asset Management Co. Ltd. bought a new stake in Mesa Laboratories during the fourth quarter worth approximately $92,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Mesa Laboratories during the 4th quarter worth $132,000. Institutional investors and hedge funds own 90.60% of the company's stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.